Patents by Inventor Todd W. Seeley

Todd W. Seeley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680048
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20210114987
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10894774
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 19, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10882827
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 5, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C Stephenson, Todd W Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10626090
    Abstract: The present invention relates to methods and compounds for regulating or enhancing ethropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 21, 2020
    Assignee: FIBROGEN INC.
    Inventors: Stephen J. Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20180208558
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: January 30, 2018
    Publication date: July 26, 2018
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20180162819
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 9920011
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 20, 2018
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced Erythropoiesis and Iron Metabolism
    Publication number: 20170267641
    Abstract: The present invention relates to methods and compounds for regulating or enhancing ethropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 17, 2017
    Publication date: September 21, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced Erythropoiesis and Iron Metabolism
    Publication number: 20170224673
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced Erythropoiesis and Iron Metabolism
    Publication number: 20170216248
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and far treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced Erythropoiesis and Iron Metabolism
    Publication number: 20170216274
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 3, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced Erythropoiesis and Iron Metabolism
    Publication number: 20150246886
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: November 19, 2013
    Publication date: September 3, 2015
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Connective tissue growth factor antisense oligonucleotides
    Patent number: 9115356
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: August 25, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Todd W. Seeley, Mark D. Sternlicht
  • Connective tissue growth factor antisense oligonucleotides
    Patent number: 8802839
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 12, 2014
    Assignee: FibroGen, Inc.
    Inventors: Mark D. Sternlicht, Todd W. Seeley
  • Connective Tissue Growth Factor Antisense Oligonucleotides
    Publication number: 20140187610
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, Mark D. Sternlicht
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8629131
    Abstract: The present invention relates to methods for increasing iron absorption in a subject by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: January 14, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8614204
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: December 24, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8609646
    Abstract: The present invention relates to methods and compounds for decreasing the expression of hepcidin, a protein associated with regulation of iron metabolism.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 17, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8604013
    Abstract: The present invention relates to methods for treating anemia in a subject having a low percent transferrin saturation by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson